Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Binding of bacteria to magnetic nanoparticles in suspension: Experiments and kinetic models.

Biotechnology progress·2026
Same author

Ultrasound-triggered doxorubicin targeted delivery for liver cancer treatment: Reduced toxicity and improved efficacy.

PloS one·2026
Same author

Metal-Organic Framework-Based Drug Delivery Systems for Cancer Therapy: A Review.

International journal of molecular sciences·2026
Same author

FeBTC as peroxidase mimic for colorimetric cholesterol detection.

Scientific reports·2025
Same author

The Emerging Role of MXenes in Cancer Treatment.

International journal of molecular sciences·2025
Same author

Autonomous Implants.

Advanced materials (Deerfield Beach, Fla.)·2025

Related Experiment Video

Updated: Jun 18, 2025

3D Cell-Printed Hypoxic Cancer-on-a-Chip for Recapitulating Pathologic Progression of Solid Cancer
10:51

3D Cell-Printed Hypoxic Cancer-on-a-Chip for Recapitulating Pathologic Progression of Solid Cancer

Published on: January 5, 2021

4.7K

Targeted Cancer Therapy-on-A-Chip.

Heba Abed1, Remya Radha1, Shabana Anjum1

  • 1Department of Chemical and Biological Engineering, American University of Sharjah, Sharjah, UAE.

Advanced Healthcare Materials
|August 5, 2024
PubMed
Summary

Cancer-on-a-chip (CoC) platforms offer a novel in vitro method for developing and testing targeted cancer therapies (TCTs). These advanced models show promise for accelerating TCT development and clinical translation.

Keywords:
3D culturechemotherapydrug deliverymicrofluidicorgan‐on‐a‐chiptargeting

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K
Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
09:53

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography

Published on: August 16, 2020

7.2K

Related Experiment Videos

Last Updated: Jun 18, 2025

3D Cell-Printed Hypoxic Cancer-on-a-Chip for Recapitulating Pathologic Progression of Solid Cancer
10:51

3D Cell-Printed Hypoxic Cancer-on-a-Chip for Recapitulating Pathologic Progression of Solid Cancer

Published on: January 5, 2021

4.7K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K
Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
09:53

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography

Published on: August 16, 2020

7.2K

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Drug Development

Background:

  • Targeted cancer therapy (TCT) aims to minimize side effects by selectively targeting tumor cells.
  • Traditional TCT testing relies on 2D cell cultures and animal models, which have limitations.
  • Organ-on-a-chip (OoC) technology has advanced to create cancer-on-a-chip (CoC) models for in vitro cancer research.

Purpose of the Study:

  • To review the application of CoC platforms in the development and testing of TCTs.
  • To explore CoCs for identifying target biomarkers for TCTs.
  • To examine CoCs for evaluating both free and encapsulated TCTs.

Main Methods:

  • Review of existing literature on CoC platforms and their use in TCT research.
  • Focus on three key applications: biomarker identification, testing of un-encapsulated TCTs, and testing of encapsulated TCTs.
  • Discussion of current challenges and future potential of CoC technology in TCT development.

Main Results:

  • CoC platforms can be utilized to identify potential target biomarkers for TCT development.
  • CoCs are effective for testing the efficacy of free, un-encapsulated TCTs.
  • CoCs can also be used to assess the performance of encapsulated TCTs.

Conclusions:

  • Cancer-on-a-chip technology presents a promising pre-clinical platform for TCT development.
  • CoCs can expedite the translation of TCTs from the laboratory to the clinic.
  • Overcoming challenges like system scaling and testing externally triggered therapies is crucial for future advancements.